Primary Ovarian Insufficiency Clinical Trial
Official title:
A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Normal Hysterosalpingogram and Normal Semen Analysis and Evidence of Premature Ovarian Aging (POA).
The experimental focus of this project is on the interaction of DHEA treatment on pregnancy in women with otherwise unexplained infertility and evidence of premature ovarian aging (POA).
Recruitment:
Eligible patients will be recruited by advertising on the web and in newspaper. We will
screen women under 38 years old with regular menstrual cycles and more than one year of
infertility.
Experimental plan:
1. Informed consent
2. Baseline studies
- Antral follicle counts on Day 2 - 3 of cycle
- Day 3 Serum FSH, LH, E2, Prog, DHEA, DHEAS, testosterone, AMH, Fragile X
3. Randomization for pretreatment
- Group A: DHEA (25 mg three times per day)
- Group B: Placebo
4. Monitoring during treatment
- All participants will have:
- USG for follicle measurement
- Repeat serum, FSH, E2, DHEA, DHEAS, testosterone, AMH monthly during treatment.
- Physical examination
- Completion of study questionnaire regarding possible androgen effects of treatment
5. Analysis plan:
- Primary Outcome
- Pregnancy
- Pregnancy rates will be compared using logistic regression with age and
pre-treatment AMH as covariates.
- Secondary Outcomes
- Endocrine Factors
- Androgen side effects
- Primary analysis. We will perform a factorial ANOVA for the two pretreatment
factors DHEA and Placebo. Baseline AMH and age as main covariates
- Secondary analysis.
- Examine rate of change of estradiol and other endocrine response over the four
cycles of pretreatment
- Compare antral follicle counts across pretreatment cycles between groups
- Compare possible androgen related effects
- Power considerations:
- Power assumptions: alpha 0.05; 80% power
- Pregnancy rate for unexplained infertility is 2% per cycle.
- Intervention will improve pregnancy rate to 5% per cycle.
- Patients will be treated for 8 cycles.
- Cumulative pregnancy rate for control patients - 13%
- Cumulative pregnancy rate for Treated patients - 30%
- Require 91 patients to complete treatment in each group.
- Allow for 20% dropout ( 91* 1.2) will need 109 patients randomized to each group.
- Randomization:
Randomization will be by permuted blocks in order to maintain an even distribution among the
groups (because of the small numbers of participants)
- Human subjects issues
- Potential risks associated with DHEA use
- Potential risk of delay of treatment for 8 months and possible natural continued loss
of fertility
- Informed consent issues
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02871986 -
Pubertal Induction in Individuals With Hypogonadism
|
N/A | |
Recruiting |
NCT02322060 -
In Vitro Activation of Dormant Follicles for Patients With Primary Ovarian Insufficiency
|
||
Recruiting |
NCT06167135 -
Polycystic Ovary Syndrome, Mitochondrial Dysfunction, Obesity, Insulin Resistance Infertility (POMODORI) Cohort
|
||
Active, not recruiting |
NCT04675970 -
Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy
|
||
Completed |
NCT04943354 -
Associations of Combinations of Single-nucleotide Polymorphisms in Women With Premature Ovarian Failure
|
N/A | |
Recruiting |
NCT03518918 -
Establishing the Diagnosis Standard and Analysis the Risk Factors of POI in Chinese Women
|
||
Recruiting |
NCT05021094 -
Clinical Observation on Kuntai Capsule in Treating Early-onset Ovarian Hypofunction
|
Phase 4 | |
Active, not recruiting |
NCT02795000 -
Development a Predictive Nomogram for Primary Ovarian Insufficiency
|
||
Suspended |
NCT03021915 -
Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure
|
N/A | |
Completed |
NCT01436513 -
A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.
|
Phase 1 | |
Recruiting |
NCT06117982 -
The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
|
Phase 2 | |
Recruiting |
NCT02068976 -
Observational Epidemiologic Study in Women With Premature Ovarian Failure (POF)
|
||
Completed |
NCT01973075 -
Genetic Etiology in Premature Ovarian Insufficiency
|
N/A | |
Completed |
NCT03568708 -
Primary Ovarian Insufficiency: Phenotype and Optimal Treatment
|
Phase 3 | |
Not yet recruiting |
NCT02757469 -
Oral Contraceptives as Infertility Treatments for Premature Ovarian Failure
|
N/A | |
Completed |
NCT02091128 -
Pregnancy Chances in Classic Galactosemia
|
N/A | |
Recruiting |
NCT03496636 -
Autologous Ovarian Tissue Transplantation
|
N/A | |
Active, not recruiting |
NCT05737329 -
Efficacy, Safety, and Tolerability of Higher Doses Estrogen Therapy in Women With Premature Ovarian Insufficiency
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02922348 -
Hormone Replacement for Premature Ovarian Insufficiency
|
Phase 3 | |
Completed |
NCT05310617 -
Parental Project and Premature Ovarian Insufficiency
|